Menu

Tasmanian Devil Cancer Immunotherapy

Researchers in Australia claim to have successfully used immunotherapy to treat devil facial tumor disease.

Mar 13, 2017
Bob Grant

WIKIMEDIA, KERESHScientists working to slow the spread of a deadly facial cancer through populations of the Tasmania’s iconic marsupial Sarcophilus harrisii, or the Tasmanian devil, have announced progress by injecting live cancer cells into individuals with the disease. The study, which reports that some golf-ball-size tumors disappeared entirely after the injections, was published Thursday (March 9) in Scientific Reports.

“When we saw those tumors get smaller it was so exciting,” University of Tasmania immunologist Greg Woods told BBC News. “This is almost a eureka moment for us because it's the first time we can say for sure that it was the immunotherapy that was making the tumor shrink.”

See: “Tasmanian Devils Developing Resistance to Transmissible Cancer

The team of researchers, which included scientists from the United Kingdom and Denmark, administered devil facial tumor disease (DFTD) cells to six animals with the cancer. The cells, which expressed the surface major histocompatibility complex (MHC)-I molecule typically missing from DFTD tumors, allowed immune cells to infiltrate and shrink the cancerous growths. “We used the cancer cells, cultured them in a laboratory, and made them express genes that made them become visible to the devils' immune systems,” Woods told the Australian Broadcasting Corporation.

The findings may point the way toward a more effective vaccine that could protect remaining devil populations from DFTD. “The current immunization process uses dead (tumor) cells, whereas this one used live cells, so if we somehow get a combination of the two then we might have a better vaccine,” Woods said.

But protecting wild populations with vaccines is not so easy. “It's not feasible to track down and immunize every animal in the wild,” Bruce Lyons, a University of Tasmania researcher and coauthor told BBC News.

See: “The Devil’s Details

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
NRGene has launched a new product that aims to empower breeding and maximize agricultural yield as part of the Denovo assembly product suite offered by the company.
Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!